These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 19229702

  • 21. Cardiovascular events in patients with COPD: TORCH study results.
    Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Crim C, Willits LR, Yates JC, Vestbo J, TORCH Investigators.
    Thorax; 2010 Aug; 65(8):719-25. PubMed ID: 20685748
    [Abstract] [Full Text] [Related]

  • 22. Mega trials in COPD--clinical data analysis and design issues.
    Suissa S, Ernst P.
    Pneumonol Alergol Pol; 2011 Aug; 79(3):227-31. PubMed ID: 21509736
    [Abstract] [Full Text] [Related]

  • 23. Management of chronic obstructive pulmonary disease: moving beyond the asthma algorithm.
    Gordon E, Lazarus SC.
    J Allergy Clin Immunol; 2009 Nov; 124(5):873-80; quiz 881-2. PubMed ID: 19895979
    [Abstract] [Full Text] [Related]

  • 24. Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients.
    Johnson M, Agusti AG, Barnes NC.
    COPD; 2008 Dec; 5(6):369-75. PubMed ID: 19353351
    [Abstract] [Full Text] [Related]

  • 25. Effects of tiotropium or combined therapy with salmeterol on hyperinflation in COPD.
    Eguchi Y, Tateishi Y, Umeda N, Yoshikawa T, Kamoi H, Kanazawa H, Kudoh S, Hirata K, Fujimoto S.
    Osaka City Med J; 2007 Jun; 53(1):25-34. PubMed ID: 17867631
    [Abstract] [Full Text] [Related]

  • 26. Tiotropium: a bronchodilator for chronic obstructive pulmonary disease.
    Somand H, Remington TL.
    Ann Pharmacother; 2005 Sep; 39(9):1467-75. PubMed ID: 16030078
    [Abstract] [Full Text] [Related]

  • 27. Superiority of "triple" therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD.
    Singh D, Brooks J, Hagan G, Cahn A, O'Connor BJ.
    Thorax; 2008 Jul; 63(7):592-8. PubMed ID: 18245142
    [Abstract] [Full Text] [Related]

  • 28. [Long-term trials assessing pharmacological treatments in COPD: lessons and limitations].
    Marchand E.
    Rev Mal Respir; 2010 Feb; 27(2):125-40. PubMed ID: 20206061
    [Abstract] [Full Text] [Related]

  • 29. Outcomes and costs associated with initial maintenance therapy with fluticasone propionate-salmeterol xinafoate 250 microg/50 microg combination versus tiotropium in commercially insured patients with COPD.
    Dalal AA, Candrilli SD, Davis KL.
    Manag Care; 2011 Aug; 20(8):46-50, 53-5. PubMed ID: 21887993
    [Abstract] [Full Text] [Related]

  • 30. Fluticasone/salmeterol: labeling change.
    Prescrire Int; 2008 Dec; 17(98):229. PubMed ID: 19418648
    [Abstract] [Full Text] [Related]

  • 31. [Debates surrounding COPD].
    Tillie-Leblond I, Housset B.
    Rev Mal Respir; 2010 Feb; 27(2):106-7. PubMed ID: 20206057
    [No Abstract] [Full Text] [Related]

  • 32. Long-acting anticholinergic use in chronic obstructive pulmonary disease: efficacy and safety.
    Tashkin DP.
    Curr Opin Pulm Med; 2010 Mar; 16(2):97-105. PubMed ID: 20019615
    [Abstract] [Full Text] [Related]

  • 33. Risk of hospitalizations/emergency department visits and treatment costs associated with initial maintenance therapy using fluticasone propionate 500 microg/salmeterol 50 microg compared with ipratropium for chronic obstructive pulmonary disease in older adults.
    Blanchette CM, Akazawa M, Dalal A, Simoni-Wastila L.
    Am J Geriatr Pharmacother; 2008 Aug; 6(3):138-46. PubMed ID: 18775388
    [Abstract] [Full Text] [Related]

  • 34. A 4-year trial of tiotropium in chronic obstructive pulmonary disease.
    Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M, UPLIFT Study Investigators.
    N Engl J Med; 2008 Oct 09; 359(15):1543-54. PubMed ID: 18836213
    [Abstract] [Full Text] [Related]

  • 35. Mono- and combination therapy of long-acting bronchodilators and inhaled corticosteroids in advanced COPD.
    Ohar JA, Donohue JF.
    Semin Respir Crit Care Med; 2010 Jun 09; 31(3):321-33. PubMed ID: 20496301
    [Abstract] [Full Text] [Related]

  • 36. Long-acting bronchodilator therapy for the treatment of chronic obstructive pulmonary disease.
    Chen AM, Bollmeier SG, Finnegan PM.
    Ann Pharmacother; 2008 Dec 09; 42(12):1832-42. PubMed ID: 18957624
    [Abstract] [Full Text] [Related]

  • 37. Management of patients with COPD: a comparison of the INSPIRE and TORCH studies.
    Middleton PG.
    Am J Respir Crit Care Med; 2008 Jul 01; 178(1):106; author reply 106-7. PubMed ID: 18565964
    [No Abstract] [Full Text] [Related]

  • 38. Bias due to withdrawal in long-term randomised trials in COPD: evidence from the TORCH study.
    Vestbo J, Anderson JA, Calverley PM, Celli B, Ferguson GT, Jenkins C, Yates JC, Jones PW.
    Clin Respir J; 2011 Jan 01; 5(1):44-9. PubMed ID: 21159140
    [Abstract] [Full Text] [Related]

  • 39. Outcomes associated with tiotropium use in patients with chronic obstructive pulmonary disease.
    Lee TA, Wilke C, Joo M, Stroupe KT, Krishnan JA, Schumock GT, Pickard AS.
    Arch Intern Med; 2009 Aug 10; 169(15):1403-10. PubMed ID: 19667304
    [Abstract] [Full Text] [Related]

  • 40. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD.
    Najafzadeh M, Marra CA, Sadatsafavi M, Aaron SD, Sullivan SD, Vandemheen KL, Jones PW, Fitzgerald JM.
    Thorax; 2008 Nov 10; 63(11):962-7. PubMed ID: 18621985
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.